Business Description
Actuate Therapeutics Inc
NAICS : 541715
SIC : 2836
ISIN : US0050831009
Description
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3?, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.96 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.29 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.81 | |||||
| 9-Day RSI | 44.6 | |||||
| 14-Day RSI | 44.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.68 | |||||
| Quick Ratio | 1.68 | |||||
| Cash Ratio | 1.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -524.71 | |||||
| ROIC % | -545.18 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 27.48 | |||||
| Price-to-Tangible-Book | 27.89 | |||||
| EV-to-EBIT | -4.87 | |||||
| EV-to-EBITDA | -4.87 | |||||
| EV-to-FCF | -6.2 | |||||
| Price-to-Net-Current-Asset-Value | 27.89 | |||||
| Price-to-Net-Cash | 31.38 | |||||
| Earnings Yield (Greenblatt) % | -20.53 | |||||
| FCF Yield % | -16.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACTU
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Actuate Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.832 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 44.35 | ||
| 14-Day ATR ($) | 0.980959 | ||
| 20-Day SMA ($) | 8.1365 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 5.51 - 10.162 | ||
| Shares Outstanding (Mil) | 19.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Actuate Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Actuate Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Actuate Therapeutics Inc Frequently Asked Questions
What is Actuate Therapeutics Inc(ACTU)'s stock price today?
The current price of ACTU is $7.53. The 52 week high of ACTU is $10.16 and 52 week low is $5.51.
When is next earnings date of Actuate Therapeutics Inc(ACTU)?
The next earnings date of Actuate Therapeutics Inc(ACTU) is 2025-02-28 Est..
Does Actuate Therapeutics Inc(ACTU) pay dividends? If so, how much?
Actuate Therapeutics Inc(ACTU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers